CD57 Expression and Cytokine Production by T Cells in Lesional and Unaffected Skin from Patients with Psoriasis
Carregando...
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
TINCATI, Camilla
MILUSH, Jeffrey M.
HO, Emily L.
NDHLOVU, Lishomwa C.
YORK, Vanessa A.
KEATING, Sheila M.
NORRIS, Philip J.
Citação
PLOS ONE, v.8, n.2, article ID e52144, 6p, 2013
Resumo
Background: The immunopathogenic mechanisms leading to psoriasis remain unresolved. CD57 is a marker of replicative inability and immunosenescence on CD8+ T cells and the proportion of CD57 expressing CD8+ T cells is increased in a number of inflammatory conditions. Methodology: We examined the expression of CD57 on T cells in the skin of patients affected with psoriasis, comparing lesional and unaffected skin. We also assessed functionality of the T cells by evaluating the secretion of several inflammatory cytokines (IL-17A, IFN-gamma, IL-2, IL-33, TNF-alpha, IL-21, IL-22, and IL-27), from cell-sorted purified CD4+ and CD8+ T cells isolated from lesional and unaffected skin biopsies of psoriasis patients. Principal Findings: We observed that the frequency of CD57+CD4+ and CD57+CD8+ T cells was significantly higher in unaffected skin of psoriasis patients compared to lesional skin. Sorted CD4+ T cells from psoriatic lesional skin produced higher levels of IL-17A, IL-22, and IFN-gamma compared to unaffected skin, while sorted CD8+ T cells from lesional skin produced higher levels of IL-17, IL-22, IFN-gamma, TNF-alpha, and IL-2 compared to unaffected skin. Conclusions/Significance: These findings suggest that T cells in unaffected skin from psoriasis patients exhibit a phenotype compatible with replicative inability. As they have a lower replicative capacity, CD57+ T cells are less frequent in lesional tissue due to the high cellular turnover.
Palavras-chave
Referências
- Arai K, 1998, CLIN EXP IMMUNOL, V111, P345
- Boniface K, 2005, J IMMUNOL, V174, P3695
- Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
- Cameron AL, 2002, ARCH DERMATOL RES, V294, P363, DOI 10.1007/s00403-002-0349-4
- Caruso R, 2009, NAT MED, V15, P1013, DOI 10.1038/nm.1995
- Chattopadhyay PK, 2009, J LEUKOCYTE BIOL, V85, P88, DOI 10.1189/jlb.0208107
- Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247
- Clark RA, 2011, J INVEST DERMATOL, V131, P283, DOI 10.1038/jid.2010.374
- Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59
- Evans TG, 1999, AIDS, V13, P1139, DOI 10.1097/00002030-199906180-00019
- Focosi D, 2010, J LEUKOCYTE BIOL, V87, P107, DOI 10.1189/jlb.0809566
- Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173
- Iking-Konert C, 2009, CLIN EXP RHEUMATOL, V27, pS19
- Le Priol Y, 2006, J IMMUNOL, V177, P5145
- Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308
- Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213
- Mak R K H, 2009, Actas Dermosifiliogr, V100 Suppl 2, P2
- Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595
- Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041
- Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x
- Ortega C, 2009, J LEUKOCYTE BIOL, V86, P435, DOI [10.1189/JLB.0109046, 10.1189/jlb.0109046]
- Palmer BE, 2005, J IMMUNOL, V175, P8415
- Plant D, 2006, EXP DERMATOL, V15, P900, DOI 10.1111/j.1600-0625.2006.00486.x
- Res PCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014108
- Sabat R, 2007, EXP DERMATOL, V16, P779, DOI 10.1111/j.1600-0625.2007.00629.x
- Shibata S, J INVEST DERMATOL, V130, P1034
- Simpson RJ, 2008, BRAIN BEHAV IMMUN, V22, P544, DOI 10.1016/j.bbi.2007.11.002
- Stritesky GL, 2008, J IMMUNOL, V181, P5948
- Suarez-Farinas M, 2011, J INVEST DERMATOL, V131, P391, DOI 10.1038/jid.2010.280
- Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124
- Tarazona R, 2000, MECH AGEING DEV, V121, P77
- Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x
- Theoharides TC, P NATL ACAD SCI US, V107, P4448
- Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497
- Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503
- Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001
- Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505